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Targeting Human Acute Myeloid Leukemia Cells Using Human 
Recombinant Arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-
Induced Arginine Depletion 
 
 
Rita Farid Tanios 
 
 
Abstract 
 
Acute myeloid leukemia (AML) is the most common leukemia in adults. With current 
chemotherapy protocols, patients have poor prognosis and more than 10,000 patients die 
yearly of AML. Therefore new treatment to improve survival rate are needed. In this study, 
we attempt to target AML cells using a pegylated recombinant human Arginase I cobalt 
[HuArgI (Co)-PEG5000].  
HuArgI (Co)-PEG5000 was tested on ten human AML cell lines. All were sensitive to 
arginine depletion. Human peripheral blood mononuclear cells (PBMCs) and CD34
+
 bone 
marrow progenitor blasts (BMPBs) were not sensitive to HuArgI (Co)-PEG5000-mediated 
arginine depletion demonstrating that arginine deprivation selectively targets AML cells 
while sparing normal hematopoietic cells. Exogenous L-citrulline addition at low 
concentrations (1.14 to 114 µM) did not rescue cells from HuArgI (Co)-PEG5000 induced 
cytotoxicity. However  only at the concentrations of 1.14 and 11.4 mM, the addition of 
exogenous L-citrulline reversed the  sensitivity of five AML cell lines to HuArgI (Co)-
PEG5000-induced arginine depletion. Furthermore, the sensitivity of AML cells to HuArgI 
(Co)-PEG5000-induced arginine depletion in the presence or absence of L-citrulline was 
reliant on the expression levels of argininosuccinate synthetase-1 (ASS1). The cell lines that 
did not express ASS1 were not rescued by L-citrulline. Addition of the autophagy inhibitor 
chloroquine increased the sensitivity of AML cell lines to HuArgI (Co)-PEG5000-mediated 
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arginine depletion indicating that autophagy is activated and plays a protective role in AML 
cells. Staining for annexin V/PI and active caspases showed an increase in cells stained 
positively with both annexin V and PI and the absence of caspase activation indicating that 
HuArgI (Co)-PEG5000-mediated arginine depletion in AML cells induces caspase-
independent, nonapoptotic cell death.  
In this study, we have demonstrated that AML cells lines are sensitive to arginine depletion 
and thus are auxotrophic for arginine and can be selectively treated by HuArgI (Co)-
PEG5000 hence proving that L-Arginine deprivation is a potential selective and potent 
selective treatment for AML. 
Keywords: HuArgI(Co)-PEG5000, AML, Arginine, Autophagy, ASS, Citrulline, 
Chloroquine, Auxotrophy 
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  CHAPTER ONE 
0. INTRODUCTION 
 
The history of AML 
Leukemia was first published in 1827 when French physician Alfred-Armand-Louis-
Marie Velpeau described a case of a 63-year-old male who developed an illness 
characterized by weakness, fever, hepatosplenomegaly and urinary stones (Wiernik, 
2003).
 
He subsequently speculated that the blood of his patient consists of white 
corpuscles. In 1845, Dr John Hughes Bennett concluded that transformation occurred 
in the series of patients who died with enlarged spleens and changes in the "colors 
and consistencies of their blood".
2 
Microscopically, he saw round corpuscles which 
nucleus were generally composed of one large granule and two or three smaller 
granules (Bennett, 1845).
 
His illustrations (Bennett, 1852) (Figure 1) were the first 
published drawings of a patient with leukemia (Pillar, 2001).
 
Rudolf Virchow, a 
German pathologist, used for the first time the name `leukhemia' (Greek: "white 
blood") in 1847 (Virchow, 1847).
 
 
Figure 1. The microscopic appearance of blood as seen by JH Bennett (Bennett, 
1852). 
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In 1889, Wilhelm Ebstein differentiated the acute and rapidly progressive leukemia, 
from the more indolent chronic leukemia (Ebstein, 1889).
 
Finally, in 1900, Naegeli 
described the myeloblast which he differentiated from the lymphoblast. He stated 
that the presence of myeloblasts or lymphoblasts in the circulating blood formed the 
diagnosis of leukemia (Naegeli, 1900).
 
Further understanding of AML occurred rapidly in the last century, and in 2008, 
AML became the first cancer genome to be fully sequenced (Ley et al., 2008). 
Pathophysiology and clinical aspects of AML 
AML is a malignant disease of the bone marrow. It is characterized by the rapid and 
abnormal growth of the myeloid line of blood cells. These factors lead to a 
maturational arrest of bone marrow cells in the earliest stages of differentiation 
resulting in the reduction of normal cell production, and the accumulation of poorly 
differentiated blasts in the bone marrow, liver or spleen (Estey & Dohner, 2006). 
Myelodysplastic syndromes, familial syndromes, environmental factors or drug 
exposure, and de novo mutations are implicated in the pathogenesis of AML. The 
symptoms of AML are related to bone marrow failure which gives rise to anemia, 
thrombocytopenia and neutropenia and from organ infiltration with leukemic white 
cells (Lowenberg, Downing, & Burnett, 1999). There are two main classifications for 
AML; the World Health Organization (WHO) classification where multiple factors 
are included such as morphology, cytogenetics, molecular genetics, and 
immunological markers (Vardiman, Harris, & Brunning, 2002)
 
and the French-
American-British (FAB) classification that divide AML based on the cell type and 
the level of maturation (Bennett et al., 1985). 
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AML is the most common acute leukemia in the adult population with 
estimated 14,590 new cases in the United States in 2013 (American Cancer Society, 
2012).
 
The 5-year survival rate is only 25%; this is mainly due to an increased rate of 
relapse secondary to the persistence of myeloblasts in the bone marrow. Adverse 
prognostic factors include increasing age, high white cell count at presentation, 
secondary AML and unfavorable cytogenetic abnormalities (Dohner et al., 2010). 
The leukemia initiating cell 
Tumor cells, solid and leukemic, are clinically, genetically and phenotypically 
heterogeneous (Dick, 2008). Only a clone of cells, the leukemia initiating cells 
(LICs), can initiate and maintain tumor growth, while the rest of the tumor is non-
tumorigenic and consists the bulk of the tumor (Bonnet & Dick, 1997).
 
LICs are 
CD34+ CD38- and constitute less than 1% of the total blasts (Lapidot et al., 1984). 
LICs possess the same fundamental characteristics as a normal hematopoietic stem 
cell (HSC), such as pluripotency and self-renewal (McCulloch, 1983). Therefore, 
leukemia is the consequence of a deregulation of HSC (Figure 2). 
 
 
Figure 2. Organization of normal and AML hematopoietic system (Bonnet & Dick, 
1997). 
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Molecular mechanism of AML 
Chromosome changes such as inversions, balanced translocations, monosomies, 
trisomies and deletions are detected around 55% of adults with AML. These changes 
constitute the most important diagnostic, therapeutic and prognostic factors (Mrózek, 
Heerema, & Bloomfield, 2004).
 
Furthermore, current chemotherapeutic agents are 
being developed to target these mutations. About 50% of AML patients have a 
normal cytogenetic profile. This group is called cytogenetically normal acute 
myeloid leukemia (CN-AML). Several mutations make this group (Figure 3) such as 
the nucleophosmin 1 (NPM1) gene, the CCAAT/enhancer binding protein alpha 
(CEBPA) gene, the fms-related tyrosine kinase 3 (FLT3) gene, the mixed-lineage 
leukemia (MLL) gene, the Wilms tumor 1 (WT1) gene, the neuroblastoma RAS viral 
oncogene homolog (NRAS) gene, and the runt-related transcription factor 
1(RUNX1) gene (Dohner, 2007; Mrózek et al., 2007). These gene mutations also 
occur in patients with abnormal karyotypes. 
 
Figure 3. Cytogenetic subgroups of AML - excluding AML-M3 (Dohner & Dohner, 
2008) 
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Figure 4. Molecular heterogeneity of cytogenetically normal AML (Dohner et al., 
2010). 
 
The MRC trial in 1998 has categorized the prognosis of AML patients into 3 groups, 
good, intermediate and poor depending on cytogenetic abnormalities (Table 1). But 
recently, a fourth category and new genetic mutations were added (Table 2) 
 
Table 1. Prognosis and cytogenetics of AML (Grimwade et al., 1998) 
Risk Category Abnormality 
Good t(8;21), t(15;17), inv(16) 
Intermediate 
Normal, +8, +21, +22, del(7q), del(9q), Abnormal 11q23, all other 
structural or numerical changes 
Poor -5, -7, del(5q), Abnormal 3q, Complex cytogenetics 
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Table 2. Correlation of cytogenetic and molecular genetic data in AML (Dohner et 
al., 2010) 
Genetic group Subsets 
Favorable 
t(8;21)(q22;q22); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
Mutated NPM1 without FLT3-ITD (normal karyotype) 
Mutated CEBPA (normal karyotype) 
Intermediate-I 
Mutated NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 without FLT3-ITD (normal karyotype) 
Intermediate-II 
t(9;11)(p22;q23); MLLT3-MLL 
Cytogenetic abnormalities not classified as favorable or adverse 
Adverse 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
t(6;9)(p23;q34); DEK-NUP214 
t(v;11)(v;q23); MLL rearranged 
−5 or del(5q); −7; abnl(17p); complex karyotype 
 
Conventional treatment of AML 
The standard therapy for AML is divided into induction and consolidation. With 
induction chemotherapy, the number of leukemic cells is reduced and patients 
achieve a complete remission. The aim of consolidation therapy is to eradicate any 
residual disease and achieve a cure. 
Cytarabine (ara-C) and an anthracycline are usually given during the induction phase 
(Dohner et al., 2010). 
Consolidation therapy includes intensive chemotherapy, prolonged maintenance 
treatment, and autologous or allogeneic hematopoietic stem cell transplantation 
(HSCT) (Löwenberg, Griffin, & Tallman, 2003).
 
Although treatment modalities have 
resulted in a high rate of complete remission, there are still an estimated 10,200 
deaths yearly and a 5-year relative survival of 25% (American Cancer Society, 
2012).
 
Thus the need for alternative approaches using more selective treatment 
modalities for targeting AML myeloblasts. One such approach consists of targeting 
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potential arginine auxotrophy of AML cells by inducing arginine deprivation using a 
pegylated human recombinant Arginase I cobalt [HuArgI (Co)-PEG5000] (Stone et 
al., 2010). 
Potential new therapy: Arginine auxotrophy 
Arginine and urea cycle 
L-Arginine is a basic amino acid (AA). It is considered a semi-essential amino acid 
or conditionally essential amino-acid since its need and production varies depending 
on the developmental age and state of disease, stress, and proliferating cells 
(Beaumier, Castillo, Yu, Ajami, & Young, 1996). It is mainly a product of diet, 
turnover of proteins, and de-novo synthesis (Morris, 2004).
 
L-Arginine is involved in many important pathways such as nitric oxide and creatine 
production, nucleotides, proline and glutamate biosynthesis. It has as well an 
immunomodulatory effect including the stimulation of T and natural killer cell 
activity, it stimulates the release of insulin-like growth factor 1, growth hormone and 
prolactin (Feun et al, 2008). 
In adults, de-novo synthesis of L-Arginine involves the intestinal-renal axis (Wu & 
Morris, 1998). Citrulline is synthesized from glutamine, glutamate and proline in the 
mitochondria of enterocytes. It is then released from the small intestine, and taken up 
by the proximal renal tubule for arginine production. L-arginine is synthesized from 
L-citrulline in two steps via the urea cycle. The argininosuccinate synthetase (ASS) 
catalyzes the conversion of aspartic acid and L-citrulline to argininosuccinate which 
is then further converted to L-arginine and fumaric acid by argininosuccinate lyase 
(ASL) (Kuo, Savaraj, & Feun, 2010). Citrulline is converted into Arginine in nearly 
all cells such as endothelial cells, macrophages, enterocytes, adipocytes and neurons 
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(Wu & Morris, 1998). L-arginine is then degraded to L-ornithine and urea by 
arginase and to citrulline and ammonium by arginine deiminase (ADI), a bacterial 
enzyme. L-ornithine is converted back to L-citrulline by ornithine transcarbamyl 
transferase (OCT) and recycled to arginine by ASS/ASL (Kuo et al., 2010). 
 
 
Figure 5. Metabolic pathways of urea cycle relevant to Arg deprivation strategy 
using PEG-Arginase (Kuo et al., 2010). 
 
ASS is ubiquitous in normal cells. However its expression differ depending on the 
cell type and extracellular factors such as cyclic AMP, IL-1, TNF-, TGF-1 and 
glutamate (Brasse-Lagnel et al., 2003; Brasse-Lagnel et al., 2005; Guei et al., 2008) 
 
ASS levels vary significantly in tumors. High levels of ASS are found in colon, 
stomach and ovarian cancer, while undetectable levels are found in mesotheliomas, 
melanoma, renal cell carcinoma, and hepatocellular carcinoma (HCC). Arginine is 
considered an essential amino-acid in tumors that depend on an abundant arginine 
reserve thus ASS negative cancers cannot survive in the absence of arginine; hence 
they are called auxotrophic for arginine (Dillon et al, 2004). 
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Two proteins were developed to achieve arginine deprivation, ADI and arginase.  
Arginine depletion: ADI and arginase 
Arginine depletion is achieved using two enzymes, arginine deiminase and arginase.  
ADI is only secreted by microorganisms. It has two disadvantages; it is highly 
immunogenic in mammals especially after repeated injections and it has a short 
circulating half-life (Ensor, Holtsberg, Bomalaski, & Clark, 2002).  
Arginase occurs in mammalian liver and other tissues. It degrades arginine in the 
urea cycle. Arginase has been described to have anti-tumor effect since the 1950s 
(Bach & Swaine, 1965). Arginase has, as well, several short comings such as short 
half-life, low affinity for arginine at physiologic pH, and an optimum pH of 9.6 
(Savoca,, Davis, van Es, McCoy, & Palczuk, 1984). 
 
Because of the short half-life of native arginase (< 30 minutes), it is very difficult to 
achieve proper therapeutic concentrations in humans. Thus pegylation is needed to 
protect arginase from the degrading enzymes and to reduce its immunogenicity 
(Figure 6). First described in the 70s, pegylation modifies the protein extensively 
with maintenance of its activity. It is the process whereby polyethylene glycol chains 
are covalently attached to protein or peptide molecules. PEG is 20,000 MW, and it 
isapproved by FDA. It is not toxic, not immunogenic, and is eliminated by the 
kidneys (Harris & Chess, 2003). 
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Figure 6. Advantages of PEGylated proteins (Veronese & Pasut, 2005). 
 
Under physiological conditions, human arginase I (HuArgI), normally conjugated to 
two Mn
2+
 ions, has reduced activity because of a minimal catalytic activity due to 
alow saturation constant (Glazer et al., 2011).
 
Furthermore, in serum, the protein 
rapidly loses the Mn
2+
 ions, which inactivates the enzyme and results in a half-life of 
4.8 hours (Stone et al., 2010).
 
Replacing Mn
2+
 with Co
2+ 
(Co-hArgI) lead to an 
increase in the enzyme activity and in serum stability (Stone et al., 2010).
 
Arginine depletion therapy and cancer 
Amino-acid depletion is now being used as treatment for some of cancers with L-
asparaginase being an approved treatment for acute lymphoblastic leukemia (ALL) 
(Hawkins et al., 2004; Muller et al., 1998). Several other cancers such as HCC, RCC, 
melanoma, prostate and head and neck cancers are being evaluated for arginase and / 
or arginine deiminase therapy.  
Leukemia 
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L-asparaginase is used for treatment of patients with ALL (Hawkins et al., 
2004; Muller et al., 1998). However, arginine depleting therapy was 
found to be 100 times more potent than asparaginase (Gong et al., 2000).
 
Recently, Hernandez et al. documented that pegylated arginase I (peg-Arg 
I) impairs the proliferation of malignant T cells (Hernandez et al., 2010).
 
Melanoma 
In 2002, Ensor et al. found that 23 melanoma cell lines were sensitive to 
ADI  with an IC50 ranging between < 0.01 and 0.3 ug/ml 
(Ensor, Holtsberg, Bomalaski, & Clark, 2002). In 2005, Ascierto et al. 
reported the results of phase I and phase II studies with 15 and 24 
metastatic patients respectively (Ascierto et al., 2005). Six of 24 patients 
(25%) responded to treatment with five showing a partial response and 
one complete response. All six patients had prolonged survival. Human 
arginase was tested later by Lam et al. They found that recombinant 
human arginase I (rhArg) inhibits the growth of melanoma cell lines in 
vitro and in vivo (Lam et al., 2011). 
Hepatocellular carcinoma (HCC) 
Similar to melanoma, ADI in HCC. Phase I/IIa trial  demonstrated that 
PEG-ADI is effective in treating some patients with advanced HCC 
(Glazer et al., 2010). In addition to ADI, arginase also proved to be 
effective in inhibiting HCC in vitro and in vivo (Cheng et al., 2007; Tsui 
et al., 2009).
 
Prostate cancer 
12 
 
Both ADI and arginase were found to cause a significant cytotoxic effect 
on prostate cancer (Hsueh et al., 2012; Kim et al., 2009). 
Other types of cancers 
In addition to melanoma, leukemia, HCC and prostate cancer, several 
other tumors were tested against arginine depletion therapy such as RCC, 
head and neck cancers and mesothelioma. Renal cell carcinoma was 
found to be highly sensitive to ADI (Yoon et al., 2004). A phase II study 
is planned to evaluate the effect of arginine depleting therapy on 
malignant mesothelioma. This clinical trial was planned after Szlosarek 
demonstrated the sensitivity of mesothelioma cell lines to arginine 
depletion treatment (Szlosarek et al., 2006). Finally, ADI treatment was 
used for head and neck cancers to which they were sensitive (Huang et 
al., 2012).
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CHAPTER TWO 
1. SPECIFIC AIMS OF THE THESIS 
 
The aims of the study are to:  
 Test potential arginine auxotrophy of AML cells using Human 
Recombinant Arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]  
 Characterize the response of AML cells to [HuArgI (Co)-PEG5000]-
induced arginine depletion. 
 Evaluate the combination therapy:  HuArgI (Co)-PEG5000 with 
Cytarabine or Doxorubicin 
 Check the effect of citrullin addition to cell lines 
 Assess the effect of HuArgI (Co)-PEG5000 on cell cycle and the type of 
cell death  
 Assess the level of ASS expression  
 
 
 
 
 
 
 
 
14 
 
CHAPTER THREE 
MATERIALS AND METHODS 
 
Expression and purification of human recombinant Arginase I 
cobalt [HuArgI (Co)-PEG5000] 
Pegylated human recombinant Arginase I cobalt [HuArgI (Co)-PEG5000] was 
expressed and purified as described previously (Stone et al., 2006).
 
Chloroquine, and 
L-citrulline were purchased from Sigma-Aldrich. 
Cells and cell lines 
Human AML cell lines HL60, U937, ML1, ML2, Mono-Mac-1, Mono-Mac-6, KG-1, 
TF1-vRaf, TF1-vSrc and TF1-HaRas were grown as described previously (Ramage 
et al., 2003).
 
Human CD34
+
 progenitor bone marrow blasts (PBMBs) were purchased from (Lonza, 
Basel, Switzerland) and grown in StemlineII
TM
 hematopoietic stem cell expansion 
medium (Sigma-Aldrich) supplemented with 10 ng/ml IL-3, 5 ng/ml granulocyte 
colony stimulating factor (G-CSF), 5 ng/ml granulocyte macrophage colony 
stimulating factor (GMCSF), 10 ng/ml stem cell factor (SCF), 10 µg/ml insulin and 
100 µg/ml transferrin (Sigma-Aldrich), as described previously (Blair, Hogge, & 
Sutherland, 1998).
 
Human peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-
Paque gradient. Briefly, 10 ml of blood were diluted 3-fold in dilution buffer 
(phosphate buffered saline, 2 mM EDTA), layered, carefully, over 10 ml ficoll-paque 
and centrifuged at 4500 rpm for 20 min. The layer corresponding to PBMCs was 
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isolated, transferred to 45 ml of dilution buffer, centrifuged twice at 3000 rpm for 20 
min at 20
o
C and the resulting pellet re-suspended in 10 ml growth media. 
Proliferation inhibition assay (cytotoxicity) 
Sensitivity of AML cell lines, PBMCs and Human CD34
+
PBMBs to HuArgI (Co)-
PEG5000, in the presence and absence of excess exogenous L-citrulline, was 
determined using a proliferation inhibition assay as described previously (Abi-Habib 
et al., 2005). Briefly, aliquots of 10
4
 cells/well (10
5
 cells/well for PBMCs), in 100 l 
cell culture medium, were plated in a flat-bottom 96-well plate (Corning Inc. 
Corning, NY). L-citrulline was added to cells at concentrations of 1.14 µM, 11.4 µM, 
114 µM, 1.14 mM and 11.4 mM. This was followed by the addition of 50 l HuArgI 
(Co)-PEG5000 in media to each well to yield concentrations ranging from 10
-7
 to 10
-
13
 M. When Cytarabine or Doxorubicin was used, it was added as described for 
HuArgI (Co)-PEG5000 but in concentrations ranging from 10
-3
 to 10
-9
 M. Following 
a 24, 48 or 72 h  incubation at 37
o
C/5% CO2, 50 l of XTT cell proliferation reagent 
(Roche, Basel, Switzerland) were added to each well and the plates incubated for 
another 4 h. Absorbance was then read at 450 nm using a microplate reader (Thermo 
Fisher Scientific, Waltham, MA). Nominal absorbance and percent maximal 
absorbance were plotted against the log of concentration and a non-linear regression 
with a variable slope sigmoidal dose-response curve was generated along with IC50 
using GraphPad Prism 5 software (GraphPad Software, San Diego, CA). All assays 
were performed at least twice with an inter-assay range of 30% or less for IC50.  
Autophagy Assays 
The potential role played by autophagy in arginine depletion-induced cytotoxicity of 
AML cells was tested by incubating AML cells with HuArgI (Co)-PEG5000 alone 
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and in combination with the autophagy inhibitor chloroquine. Briefly, aliquots of 10
4
 
cells/well, in 100 l cell culture medium, were plated in a flat-bottom 96-well plate 
(Corning Inc. Corning, NY). Chloroquine was added to a subset of wells at a 
concentration of 10 µM and 100 mM, respectively. This was followed by the 
addition of 50 l HuArgI (Co)-PEG5000 in media to each well to yield 
concentrations ranging from 10
-7
 to 10
-13
 M and the plates were incubated for 48 h at 
37
o
C/5% CO2. This was followed by the addition of 50 l XTT cell proliferation 
reagent (Roche, Basel, Switzerland) to each well and the plates were incubated for 
another 4 h. Absorbance was then read at 450 nm using a 96-well plate reader 
(Thermo Fisher Scientific, Waltham, MA). Data was analyzed using GraphPad Prism 
V software (GraphPad Software, San Diego, CA) and the IC50 (inhibitory 
concentration 50) of HuArgI (Co)-PEG5000 alone or in the presence of chloroquine 
were compared. 
Cell cycle analysis 
The impact of [HuArgI (Co)-PEG5000]-induced arginine depletion on the cell cycle 
of AML cells was determined using Propidium Iodide (PI)-staining on flow 
cytometry. Briefly, cells incubated with 3 different concentrations of HuArgI (Co)-
PEG5000 (100000, 3000 and 45 pM) or media alone in flat-bottom 96-well plates 
(Corning Inc. Corning, NY) for 24 and 48 h at 37
o
C/5% CO2, were harvested and 
fixed in 70% ethanol for a minimum of 24 h, at -20
o
C. Cells were then incubated in 
500 l PI staining solution (50 µg/ml) for 40 min at 37oC. Samples were then read on 
a C6 flow cytometer (BD Accuri, Ann Arbor, MI) and total cell DNA content was 
measured on FL2-A. Percent of cells in G0/G1, S and G2/M phase was determined in 
control cells and in cells treated with the 3 different concentrations of HuArgI (Co)-
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PEG5000 (100000, 3000 and 45 pM) following gating for the cell population on 
width versus forward scatter. 
 Intracellular Staining and Flow Cytometry Analysis 
Expression levels of Argininosuccinate Synthetase 1 (ASS-1) were assessed using 
flow cytometry as described previously (Kassab et al., 2013). Approximately 3x10
6
 
cells were fixed in 70% ethanol for 15 min. Cells were then incubated with a 1/100 
dilution of anti-ASS-1 mouse monoclonal antibodies (Sigma, Danvers, MA) in 
antibody binding buffer containing 0.05% Triton-X 100, for 1 h at 37
o
C, followed by 
a 30-minute incubation with a 1/100 dilution of a FITC-conjugated rabbit anti-mouse 
polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Isotypic control 
consisted offixed cells incubated with a 1/100 dilution of mouse IgG (Sigma, 
Danvers, MA) and a FITC-conjugated rabbit anti-mousepolyclonal antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA). Samples were then washed once, re-
suspended in binding buffer and analyzed using a C6 flow cytometer (BD Accuri, 
Ann Arbor, MI). The presence of ASS-1 was analyzed and compared with that of the 
isotopic control. Positivity for the presence of ASS-1 was determined using the ratio 
of fluorescence intensity (RFI) between the mean fluorescence intensity (MFI) of the 
stained cells and the MFI of the isotypic control. RFI  3.0 was considered positive. 
Analysis of Cell Cytotoxicity 
Determination of apoptotic versus non-apoptotic cell death was carried out using an 
Annexin V-fluorescin Isothiocyanate (Annexin V-FITC) and Propidium Iodide (PI) 
labeled apoptosis/necrosis detection kit (Abcam, Cambridge, MA) and a FITC-
conjugated active caspase inhibitor (ApoStat Apoptosis Detection Kit, R&D 
Systems, Abingdon, England) on flow cytometry. Briefly, 10
4
 cells/well were plated 
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in 100 l media in a flat-bottom, 96-well plate and were incubated with either 100 l 
of medium alone (control cells) or medium containing three different concentrations 
of HuArgI (Co)-PEG5000 (as described above under cell cycle analysis) for 24 and 
48 h at 37
o
C/5% CO2. Cells were then harvested and incubated with a FITC-
conjugated annexin V antibody (2.5 mg/ml and PI (5 mg/ml) in antibody binding 
buffer for 45 min at 37
o
C or incubated with 0.5 µg/ml of apostat for 30 min then 
harvested. Cells were then read using a C6 flow cytometer. Annexin V/PI data was 
analyzed on FL1-H versus FL2-H scatter plot and active caspases were detected on 
FL1-H. Unstained cells were used as negative control. Cells had to show positive 
annexin V staining, negative PI staining and positive active caspase staining to be 
considered apoptotic, while cells positive for both annexin V and PI staining and 
negative for active caspase staining were considered non-apoptotic. 
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CHAPTER FOUR 
RESULTS 
 
Cytotoxicity of HuArgI (Co)-PEG5000 
We tested the cytotoxicity of pegylated human recombinant Arginase I cobalt 
[HuArgI (Co)-PEG5000] on a panel of 10 human AML cell lines. All the AML cell 
lines tested were sensitive to the HuArgI (Co)-PEG5000-mediated arginine depletion 
with IC50 = 14-552 pM and percent cell kill at highest concentration > 75%, at 48 h 
post-treatment. (Table 3, Figure 7D).  
Table 3. Sensitivity of human AML cell lines, PBMCs and CD34+ bone marrow 
progenitor blasts (BMPBs) to HuArgI (Co)-PEG5000 in the presence and absence of 
exogenous L-citrulline (1.14µM and 11.4 mM). 
Cells and cell lines 
HuArgI (Co)-
PEG5000 
HuArgI (Co)-
PEG5000 + L-
cit (1.14µM) 
HuArgI (Co)-
PEG5000 + L-
cit (11.4mM) 
Human AML cell lines    
U937 58.0 pM 61.0 pM >10,000 pM 
ML1 200 pM 246 pM >10,000 pM 
TF1-VRaf 207 pM 260 pM 304 pM 
TF1-HaRas 284pM 253 pM 248 pM 
KG-1 320 pM NA NA 
ML2 341 pM 335 pM >10,000 pM 
Mono-Mac-1 400 pM 413 pM >10,000 pM 
Mono-Mac-6 488 pM 432 pM 463 pM 
TF1-VSrc 552 pM 586 pM 598 pM 
HL60 722 pM 756 pM >10,000 pM 
Normal human cells    
Peripheral Blood Mononuclear Cells >10,000 pM >10,000 pM NA 
CD34
+ 
Progenitor Bone Marrow Blasts >10,000 pM > 10,000 pM NA 
NA: Not available 
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B) 
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Figure 7. Non-Linear regression curves of the cytotoxicity of HuArgI (Co)-
PEG5000 (square) and HuArgI (Co)-PEG5000 + L-citrulline (11.4 mM) (triangle) on 
human AML cell lines HL60, Mono-Mac-1, U937, ML2 and ML1 (A) and TF1-
HaRas, TF1-VRaf, TF1-vSrc and Mono-Mac-6 (B). C) Non-linear regression curves 
of the cytotoxicity of HuArgI (Co)-PEG5000 on human normal PBMCs (square) and 
on Human CD34
+
 bone marrow progenitor blasts (BMPBs) (triangle). D) Compilation 
of HuArgI (Co)-PEG5000 non-linear regression curves on all cells tested. E) Non-
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linear regression curves of the combination of HuArgI (Co)-PEG5000 with 
cytarabine (U937) and doxorubicin (TF1-vRaf). 
 
Incubation times of 24, 48 and 72 h were tested and revealed an increased sensitivity 
of AML cell lines to HuArgI (Co)-PEG5000 at 48 and 72 h incubation compared to 
24 h incubation (IC50 lower by 5 to 10-fold) with no significant difference seen 
between 48 and 72 h (Data not shown). Several studies have shown that addition of 
excess exogenous L-citrulline rescues a number of cancer cell lines from arginine 
depletion-induced cytotoxicity by increasing flux through the urea cycle leading to 
an increase in intracellular arginine levels.
23
. Therefore, the inability to rescue cells 
from arginine depletion-induced cytotoxicity by the addition of excess L-citrulline is 
considered a marker of irreversible arginine auxotrophy. Addition of L-citrulline, at 
concentrations of 1.14, 11.4 and 114 µM, failed to rescue AML cells from arginine 
deprivation-induced cytotoxicity and did not affect the sensitivity of AML cell lines 
to HuArgI (Co)-PEG5000-induced arginine depletion with similar IC50 values 
observed in the presence and absence of L-citrulline (Table 3). However, increasing 
the concentration of exogenous L-citrulline to 1.14 and 11.4 mM, resulted in 
rescuing 5 out of the 9 cell lines tested (HL60, U937, ML1, ML2 and Mono-Mac-1) 
from arginine deprivation-induced cytotoxicity (Table 3, Figure 7A). The cytotoxic 
response of the remaining 4 cell lines (Mono-Mac-6, TF1-vRaf, TF1-HaRas and 
TF1-vSrc) to HuArgI (Co)-PEG5000-induced arginine depletion was not affected by 
the addition of 11.4 mM exogenous L-citrulline indicating complete arginine 
auxotrophy of these cell lines (Table 3, Figure 7B). These results demonstrate that all 
the AML cell lines tested show partial arginine auxotrophy, with a subset showing 
complete arginine auxotrophy, and are, subsequently, sensitive to the HuArgI (Co)-
PEG5000-induced arginine depletion. 
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In order to determine whether HuArgI (Co)-PEG5000-induced arginine depletion 
selectively targets AML cells while sparing normal blasts, we tested the cytotoxicity 
of HuArgI (Co)-PEG5000 on both human peripheral blood mononuclear cells 
(PBMCs) and CD34
+
 bone marrow progenitor blasts (BMPBs). Both the PBMCs and 
the CD34
+
 BMPBs were resistant to the HuArgI (Co)-PEG5000-induced arginine 
depletion with an IC50> 10,000 pM and percent cell kill at highest concentration of 
20% and 35% for PBMCs and CD34
+
 BMPBs, respectively. These findings 
demonstrate the selective cytotoxicity of HuArgI (Co)-PEG5000-induced arginine 
depletion to AML cell lines (Table 3, Figure 7C). 
In order to investigate potential additive/synergistic effects of HuArgI (Co)-
PEG5000-induced arginine depletion and standard chemotherapeutic agents in AML 
cells; we tested the cytotoxicity of a combination of HuArgI (Co)-PEG5000 and 
cytarabine or doxorubicin on our panel of AML cell lines. Three of the cell lines 
tested (TF1-vRaf, TF1-HaRas and TF1-vSrc) were not sensitive to cytarabine and 
were subsequently excluded from this analysis. Four out of the six remaining cell 
lines (HL60, U937, ML1 and ML2) showed additive/synergistic effects with IC50 
values of the combination of HuArgI (Co)-PEG5000 and cytarabine being 2.0 to 18-
fold lower than those observed with HuArgI (Co)-PEG5000 alone (Figure 7E). The 
remaining two cell lines (Mono-Mac-1 and Mono-Mac-6) did not show any additive 
or synergistic effects for the combination of HuArgI (Co)-PEG5000 and cytarabine 
with similar IC50 values observed for the combination compared to each treatment 
alone. For the doxorubicin combination, additive/synergistic effects were observed in 
6 of the cell lines tested (Figure 7E). Four cell lines (HL60, U937, ML2 and TF1-
vRaf) had IC50 values for the combination of HuArgI (Co)-PEG5000 and 
doxorubicin that were 2.5 to 5 fold lower than those observed with HuArgI (Co)-
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PEG5000 alone while another two cell lines (TF1-HaRas and TF1-vSrc) showed IC50 
values for the combination that were 4 to 5-fold lower than those observed with 
Doxorubicin alone. No additive/synergistic effects of the combination were observed 
in the remaining 3 cell lines (ML1, Mono-Mac-1 and Mono-Mac-6). This indicates 
that HuArgI (Co)-PEG5000-induced arginine depletion shows additive/synergistic 
effects with standard chemotherapeutic agents in a subset of AML cell lines. 
Cell cycle effect of HuArgI (Co)-PEG5000: 
In order to determine whether, in addition to cytotoxicity, HuArgI (Co)-PEG5000-
induced arginine depletion causes cell cycle arrest in AML cells, we determined the 
cell cycle status of our panel of AML cell lines following 24 and 48 h incubation 
with three different concentrations of the HuArgI (Co)-PEG5000(Fig. 8A and 
B).None of the cell lines tested showed any effect of HuArgI (Co)-
PEG5000treatment on cell cycle at any concentration at 48 h incubation (Fig. 8A). 
The fraction of cells in both the G0/G1 and G2/M phases decreased with increasing 
concentrations of HuArgI (Co)-PEG5000. This was accompanied by an increase in 
the fraction of cells in the pre-G0/G1 phase at the highest concentrations of HuArgI 
(Co)-PEG5000 at 48 h incubation, indicating that treatment induces complete 
cytotoxicity in the totality of treated cells (Fig. 8A). At 24 h incubation, 2 out of 10 
cell lines (TF1-HaRas and TF1-vSrc) showed dose-dependent cell cycle arrestwhile 
the remaining cell lines did not show any effect of HuArgI (Co)-PEG5000 treatment 
on cell cycle(Fig. 8B). The fraction of cells in the G0/G1 phase increased from 
approximately 42% and 38% of the total cell population in control cells to 
approximately 54% and 53% of the total cell population, for TF1-HaRas and TF1-
vSrc respectively, following incubation with 100,000 pM of HuArgI (Co)-PEG5000 
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for 24 h. This was associated with a corresponding decrease in the percentage of cells 
in the G2/M phase.  
A) 
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B)
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Figure 8. Cell cycle analysis of the Mono-Mac-1, TF1-vSRc, HL60 and Mono-Mac-
6 (A) cell line following treatment with HuArgI (Co)-PEG5000 for 48 h and the 
TF1-vSrc, HL60 and Mono-Mac-6 cell line following treatment with HuArgI (Co)-
PEG5000 for 24 h (B). Control cells are represented in the left panels and cells 
treated with 100 nM HuArgI (Co)-PEG5000 in the right panels. Cells are gated on 
width versus forward scatter (R1). Cells in G0/G1 are gated M1, G2/M are gated M2 
and pre-G0/G1 (dead) are gated M3. Cell lines showed complete cell death following 
treatment, with no evidence of cell cycle arrest following 48 h of HuArgI (Co)-
PEG5000-induced arginine depletion. 
 
Autophagy: 
The potential role played by autophagy in the HuArgI (Co)-PEG5000-induced 
cytotoxicity of AML cells was investigated by co-incubating AML cells with HuArgI 
(Co)-PEG5000 and either the autophagy activator, trehalose or the autophagy 
inhibitor chloroquine. A subset of 3 AML cell lines was tested (TF1-vSrc, U937 and 
ML-1) and, in all three cell lines, the addition of chloroquine (10 µM) induced a 
significant increase in the sensitivity of cells to HuArgI (Co)-PEG5000 at both 24 
and 48 h incubation (Figure 9). The IC50 values obtained with the combination of 
HuArgI (Co)-PEG5000 and chloroquine were 4, 8 and 17-fold lower for TF1-vSrc, 
U937 and ML1, respectively, at 24 h and 12, 20 and 30-fold lower for TF1-vSrc, 
ML1 and U937, respectively, at 48 h, compared to IC50 values obtained with HuArgI 
(Co)-PEG5000 alone. Hence, inhibiting autophagy led to an increase in the 
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sensitivity of AML cells to arginine depletion, indicating that activation of 
autophagy, following arginine depletion, plays a protective role played against the 
HuArgI (Co)-PEG5000-induced cell death of AML cells. Additional activation of 
autophagy through the addition of trehalose only led to a modest decrease in the 
sensitivity of AML cell lines to HuArgI (Co)-PEG5000 with IC50 values increasing 
by a maximum of 2-fold in the combination of HuArgI (Co)-PEG5000 and trehalose 
compared to HuArgI (Co)-PEG5000 alone. This indicates that HuArgI (Co)-
PEG5000-induced arginine depletion leads to near maximal activation of autophagy, 
limiting the potential impact of the autophagy activator trehalose.   
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Figure 9. Sensitivity of AML cell lines to HuArgI (Co)-PEG5000 alone and in 
combination with the autophagy inhibitor chloroquine. Non-linear regression curves 
of U937 (48 h) (A), ML1 (24h) (B) and TF1-vSrc (48 h) (C) cells incubated with 
HuArgI (Co)-PEG5000 alone (square) or in combination with chloroquine (triangle). 
In the presence of chloroquine AML cell lines were significantly more sensitive to 
HuArgI (Co)-PEG5000, at both 24 and 48 h indicating the protective role played by 
chloroquine in arginine depletion-induced cell death. 
 
Analysis of Argininosuccinate synthetase 1 (ASS1) levels: 
We determined the expression levels of argininosuccinate synthetase 1 (ASS1) in 
AML cell lines and in CD34
+
 progenitor blasts using single-cell intracellular staining 
on flow cytometry. Four of the nine AML cell lines tested, ML1, ML2, U937 and 
HL60, were positive for the expression of ASS1, as evidenced by a ratio of 
fluorescence intensity (RFI) of 23.4, 3.5, 4.2 and 12.7, respectively (Fig. 10 A and 
B). The remaining five cell lines, on the other hand, Mono-Mac-1, Mono-Mac-6, 
TF1-vRaf, TF1-HaRas and TF1-vSrc, were negative for the expression of ASS1, as 
evidenced by RFI values of 1.88, 2.03, 2.63, 1.59 and 2.45, respectively (Fig. 10 C, 
D and E). Expression of ASS1 correlated with the sensitivity of cells to HuArgI 
(Co)-PEG5000-induced arginine depletion in the presence of excess (11.4 mM) 
exogenous L-citrulline in all but one cell line (Mono-Mac-1) which was rescued by 
the highest concentration of L-citrulline (11.4 mM) but was negative for ASS1 
expression. The expression pattern of argininosuccinate synthetase in AML cells 
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confirms their arginine auxotrophy and represents the underlying mechanism for 
their sensitivity to HuArgI (Co)-PEG5000-induced arginine depletion, in the 
presence and absence of excess exogenous L-citrulline. Similarly, the resistance of 
CD34
+
 progenitor bone marrow blasts to the cytotoxicity of HuArgI (Co)-PEG5000-
induced arginine depletion was supported by the expression of ASS1 in blast cells as 
evidenced by an RFI of 3.1 (Fig. 10F). 
A)
 
B) 
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F) 
 
Figure 10. Single cell,intracellular staining of argininosuccinate synthetase-1 (ASS-
1) in 4 AML cell lines, HL60 (A), ML1 (B), TF1-HaRas (C), TF1-vSrc (D), TF1-
vRaf (E) and in human CD34+ bone marrow progenitor blasts (HBMPBs) (F) using 
single-cell intracellular staining on flow cytometry. HL60, ML1 and CD34
+
 HBMPBs 
were positive for the expression of ASS1 as evidenced by a ratio of fluorescence 
intensity (RFI) > 3 between cells stained TF1-HaRas and TF1-vSrc cells were 
negative for the expression of ASS1 with RFI = 1.58 and 2.45, respectively. Cells are 
gated on width versus forward scatter (R1). 
 
Analysis of Cell Death: 
To determine the mechanism of cell death observed following HuArgI (Co)-
PEG5000-induced arginine depletion in AML cells, we tested for caspase activation 
and annexin V/PI staining in our panel of AML cell lines following treatment with 
three different concentrations of HuArgI (Co)-PEG5000 (100000, 3000 and 45 pM) 
for 24 and 48 h. Nine AML cell lines tested (TF1-vRaf, TF1-vSrc, HL60, U937, KG-
1, Mono-Mac-1, Mono-Mac-6, ML1 and ML2), showed an increase in the 
percentage of cells stained with both annexin V and PI, at both 24 and 48 h, in cells 
treated at the highest concentration of HuArgI (Co)-PEG5000 (100 nM) compared to 
controls, indicating either necrotic or late-stage apoptotic cell death (Fig, 11A). 
However, staining for active caspases revealed a total absence of active caspases in 
all AML cell lines tested, following treatment with HuArgI (Co)-PEG5000 for 24 
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and 48 h (Fig. 11B). The absence of caspase activation, in addition to the loss of 
membrane integrity as evidenced by positive PI staining, indicate that arginine 
depletion-induced cytotoxicity in AML cells is mediated through caspase-
independent, non-apoptotic mechanisms. 
A) 
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Figure 11. Analysis of the mechanism of HuArgI (Co)-PEG5000-mediated 
cytotoxicity in ML1, Mono-Mac-6 and HL60 cells using annexin V/PI (A) and active 
caspase staining on ML1(B). Cells incubated with 100 nMHuArgI (Co)-PEG5000 for 
48 h (right panel) stained positively with both annexin V (FL1-H) and PI (FL2-H). 
Incubation of HuArgI (Co)-PEG5000-treated ML1 cells with a cell permeable, FITC-
conjugated active caspase inhibitor revealed the absence of active caspases following 
incubation with HuArgI (Co)-PEG5000 (red). 
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CHAPTER FIVE 
  
                                      DISCUSSION 
Over the last three decades advances in chemotherapy have resulted in a great 
improvement in survival for most types of leukemia. However, conventional 
chemotherapy for AML has not been successful. The 5 years survival rate is only 
24% vs.  81% for CLL and 67% for ALL (American Cancer Society, 2012). Hence 
the necessity for a new treatment for AML.  In our study we have demonstrated that 
AML cells responded well to arginine depletion, thus they are auxotrophic for 
Arginine.   
All ten cell lines tested were sensitive to HuArgI (Co)-PEG5000 with IC50 values 
ranging between 78 pM for U937 and 722 pM for HL60, U937 being the most 
sensitive of all cell lines. 
Several reports have proven the sensitivity of amino acid depletion for targeting 
cancers.  
Asparagine depletion is an already approved treatment for acute lymphoblastic 
leukemia (Muller & Boos, 1998) and it is under investigation for acute myeloid 
leukemia (Agrawal et al., 2013), while renal cell carcinoma (RCC), hepatocellular 
carcinoma (HCC), head and neck cancer, melanoma, prostate cancer and T-ALL are 
being assessed for arginine depletion therapy by arginase and/or ADI (Ascierto et al., 
2005; Cheng et al., 2007; Glazer et al., 2010; Hsueh et al., 2012; Huang et al., 2012; 
Kim et al., 2009; Lam et al., 2011; Szlosarek et al., 2006; Tsui et al., 2009; Yoon et 
al., 2007).  
AML cells have not been previously investigated for Arginine auxotrophy, and the 
potential use of arginase for AML treatment has not been studied. In this study, we 
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have, for the first time, demonstrated that AML cell lines are auxotrophic for 
arginine, thus can be selectively treated with arginine depletion using a pegylated 
recombinant human arginase [HuArgI (Co)-PEG5000.  
We have also demonstrated that human peripheral blood mononuclear cells (PBMCs) 
and human bone marrow progenitor blasts (BMPBs) were not sensitive to arginine 
depletion. This indicates the selectivity of HuArgI (Co)-PEG5000 to cancer cells 
while sparing normal cells.  
Furthermore, adding exogenous L-citrulline at low concentrations, 1.14, 11.4 and 
114 µM did not rescue cells from arginine depletion-induced cytotoxicity. However 
when the concentration of L-citrulline was increased up to a concentration of 11.4 
mM, 5 AML cell lines were rescued from the cytotoxic effects of HuArgI (Co)-
PEG5000-induced arginine depletion. This indicates full arginine auxotrophy of a 
subset of AML cell lines and it confirms the possible use of HuArgI (Co)-PEG5000 
for selectively targeting of AML.  
We have also shown that arginine auxotrophy for AML cells range from partial 
auxotrophy in 5 cell lines to complete arginine auxotrophy in 4 cell lines. This is 
evidenced by the rescuing of AML cells with excess L-citrulline. Complete arginine 
auxotrophy seems to be secondary to the lack of ASS1 expression in AML cells, and 
the four cell lines that were not rescued by L-citrullin did not express ASS1. This can 
be compared to other tumors such as ALL, HCC and prostate cancer where the 
sensitivity of tumor cells was dependent on expression levels of ASS1 (Agrawal et 
al., 2013; Delage et al., 2010; Kim et al., 2009).  
Moreover, we demonstrated that the addition of HuArgI (Co)-PEG5000 to regular 
AML chemotherapeutic agents such as doxorubicin and cytarabine resulted in signs 
of synergistic/additive effects in some of the cell lines. This shows that HuArgI (Co)-
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PEG5000 may be used as a standalone treatment or in combination with standard 
chemotherapeutic agents.  
Cell cycle analysis showed that treatment with HuArgI (Co)-PEG5000 resulted in 
complete cytotoxicity in all 10 AML cell lines at 48 hours. Only two cell lines had 
limited cell cycle arrest after 24 hours of arginine depletion. This proves that HuArgI 
(Co)-PEG5000-induced arginine depletion has a strong inhibitory effect and the 
cytotoxicity is only secondary to cell death and not to cell cycle arrest, thus the 
extreme potency of HuArgI (Co)-PEG5000 to AML cells. 
Recently, autophagy has been extensively investigated as a response of tumor cells to 
several anti-cancer therapeutic drugs. However, its role in amino acid depletion has 
not been evaluated yet.  For the first time, we show that autophagy is activated after 
treatment with HuArgI (Co)-PEG5000. Cell sensitivity to HuArgI (Co)-PEG5000 
increased with the addition of chloroquine. Chloroquine is known to affect 
autophagolysosome thus inhibits autophagy (Periyasamy-Thandavan, Jiang, 
Schoenlein, & Dong, 2009).  All this proves that inhibiting autophagy leads to cell 
death, thus demonstrating that autophagy has a protective role in acute myeloid 
leukemia cells after treatment with HuArgI (Co)-PEG5000.  
In this study, we have demonstrated that AML cells can be selectively treated by 
HuArgI (Co)-PEG5000-induced arginine depletion, hence they are auxotrophic for 
arginine. We have as well shown that autophagy is activated after arginine depletion. 
This activation protects AML cell from cytotoxicity related to arginine deprivation. 
Thus, HuArgI (Co)-PEG5000 is a new and selective potential treatment for acute 
myeloid leukemia.   
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